Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2015)
- Authors:
- Bell, Richard
- Brown, Julia
- Parmar, Mahesh
- Toi, Mark
- Suter, Thomas
- Steger, Guenther
- Pivot, Xavier
- Mackey, John
- Jackisch, Christian
- Dent, Rebecca
- Hall, Peter
- Mecke, Almut
- Morales, Leilani
- Provencher, Louise
- Staroslawska, Elzbieta
- Hegg, Roberto
- Vanlemmens, Laurence
- Kirsch, Andreas
- Schneeweiss, Andreas
- Masuda, Norikazu
- Overkamp, Friedrich
- Cameron, David
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1158/1538-7445.SABCS14-PD2-2
- Subjects: QUIMIOTERAPIA; NEOPLASIAS MAMÁRIAS (TERAPIA); ANTINEOPLÁSICOS
- Language: Inglês
- Imprenta:
- Source:
- Título: Cancer Research
- ISSN: 0008-5472
- Volume/Número/Paginação/Ano: v. 75, abst. PD2-2, May, 2015
- Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium
- Este artigo NÃO possui versão em acesso aberto
-
Status: Nenhuma versão em acesso aberto identificada -
ABNT
BELL, Richard et al. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2. Acesso em: 11 mar. 2026. , 2015 -
APA
Bell, R., Brown, J., Parmar, M., Toi, M., Suter, T., Steger, G., et al. (2015). Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-PD2-2 -
NLM
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2026 mar. 11 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2 -
Vancouver
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2026 mar. 11 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2 - Eficacia, tolerabilidade e aceitabilidade do estradiol transdermico no tratamento dos sintomas da menopausa
- Sindrome do climaterio: conceito, importancia e epidemiologia
- Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study
- Câncer da mama: quadro clínico, diagnóstico e estadiamento
- Mastite puerperal
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
- Galactorreia: sindrome hiperprolactinemica
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
